-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 21, Sanofi announced that it has reached an agreement to acquire Amunix Pharmaceuticals (hereinafter referred to as "Amunix") to develop next-generation biological products
The T-cell binder (TCE) blinatumomab has previously demonstrated that redirecting T cells can extend the remission time of cancer patients
The XTEN platform introduces the precise modification of recombinant protein engineering into the field of polymer chemistry
Reference materials:
[1] Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics.
(The original text has been deleted)